Condition: Ovarian Cancer · Pancreas Cancer · Urothelial Carcinoma · Sponsor: Nammi Therapeutics Inc
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is an open-label, multicenter, first in human study to be conducted in two major parts which are further organized into two sub-parts. Part A Dose Escalation is a modified 3+3 with the first two cohorts consisting of one subject each based on the low clinical starting dose. Dose escalation in solid tumors (Part A1) will be followed by dose finding in multiple myeloma (Part A2). Part B consists of dose expansion in solid tumors (Part B1) and multiple myeloma (Part B2) using the recommended dose for expansion from Part A
This description comes directly from the study's public registry record.
David Stover, PhD · 818-926-3428 · David.Stover@nammirx.com
Always discuss trial participation with your own doctor first.
| University of Southern California | Los Angeles, California, United States | Recruiting |
| Cedars-Sanai Medical Center - Samuel Oschin Comprehensive Cancer | Los Angeles, California, United States | Recruiting |
| Cedars-Sanai Medical Center | Los Angeles, California, United States | Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport, California, United States | Recruiting |
| Sarah Cannon Research Institute - Denver DDU | Denver, Colorado, United States | Recruiting |
| Emory University - Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| New York Cancer & Blood Specialists | New York, New York, United States | Recruiting |
| University of Rochester - Wilmot Cancer Institute | Rochester, New York, United States | Recruiting |
| START San Antonio | San Antonio, Texas, United States | Recruiting |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06582017